Researchers Report First “Routine Clinical Use” of AI for Breast Biopsies
While AI as a diagnostic tool is still years away from regular clinical use, recent research is an important step.
While AI as a diagnostic tool is still years away from regular clinical use, recent research is an important step.
There were three notable CDx alliances announced in January 2023, all of which involved cancer-related solutions.
Researchers report the first-ever routine clinical use of an AI-based tool for breast cancer biopsies in a pathology lab.
Key Dx announcements last week involved companion diagnostics, liquid biopsy assays, and an RUO leukemia test.
Deals involving the development and commercialization of new cancer diagnostics and treatments were the most common in December.